Literature DB >> 22581780

Mutant superoxide dismutase 1 (SOD1), a cause of amyotrophic lateral sclerosis, disrupts the recruitment of SMN, the spinal muscular atrophy protein to nuclear Cajal bodies.

Shingo Kariya1, Diane B Re, Arnaud Jacquier, Katelyn Nelson, Serge Przedborski, Umrao R Monani.   

Abstract

Spinal muscular atrophy (SMA) and amyotrophic lateral sclerosis (ALS) are among the most common motor neuron diseases to afflict the human population. A deficiency of the survival of motor neuron (SMN) protein causes SMA and is also reported to be an exacerbating factor in the development of ALS. However, pathways linking the two diseases have yet to be defined and it is not clear precisely how the pathology of ALS is aggravated by reduced SMN or whether mutant proteins underlying familial forms of ALS interfere with SMN-related biochemical pathways to exacerbate the neurodegenerative process. In this study, we show that mutant superoxide dismutase-1 (SOD1), a cause of familial ALS, profoundly alters the sub-cellular localization of the SMN protein, preventing the formation of nuclear 'gems' by disrupting the recruitment of the protein to Cajal bodies. Overexpressing the SMN protein in mutant SOD1 mice, a model of familial ALS, alleviates this phenomenon, most likely in a cell-autonomous manner, and significantly mitigates the loss of motor neurons in the spinal cord and in culture dishes. In the mice, the onset of the neuromuscular phenotype is delayed and motor function enhanced, suggestive of a therapeutic benefit for ALS patients treated with agents that augment the SMN protein. Nevertheless, this finding is tempered by an inability to prolong survival, a limitation most likely imposed by the inexorable denervation that characterizes ALS and eventually disrupts the neuromuscular synapses even in the presence of increased SMN.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22581780      PMCID: PMC3392116          DOI: 10.1093/hmg/dds174

Source DB:  PubMed          Journal:  Hum Mol Genet        ISSN: 0964-6906            Impact factor:   6.150


  42 in total

Review 1.  The Cajal body.

Authors:  Glenn E Morris
Journal:  Biochim Biophys Acta       Date:  2008-08-03

2.  Temporal requirement for high SMN expression in SMA mice.

Authors:  Thanh T Le; Vicki L McGovern; Isaac E Alwine; Xueyong Wang; Aurelie Massoni-Laporte; Mark M Rich; Arthur H M Burghes
Journal:  Hum Mol Genet       Date:  2011-06-13       Impact factor: 6.150

3.  Spinal muscular atrophy: a timely review.

Authors:  Stephen J Kolb; John T Kissel
Journal:  Arch Neurol       Date:  2011-04-11

Review 4.  Molecular pathways of motor neuron injury in amyotrophic lateral sclerosis.

Authors:  Laura Ferraiuolo; Janine Kirby; Andrew J Grierson; Michael Sendtner; Pamela J Shaw
Journal:  Nat Rev Neurol       Date:  2011-11       Impact factor: 42.937

5.  Postsymptomatic restoration of SMN rescues the disease phenotype in a mouse model of severe spinal muscular atrophy.

Authors:  Cathleen M Lutz; Shingo Kariya; Sunita Patruni; Melissa A Osborne; Don Liu; Christopher E Henderson; Darrick K Li; Livio Pellizzoni; José Rojas; David M Valenzuela; Andrew J Murphy; Margaret L Winberg; Umrao R Monani
Journal:  J Clin Invest       Date:  2011-07-25       Impact factor: 14.808

6.  WRAP53 is essential for Cajal body formation and for targeting the survival of motor neuron complex to Cajal bodies.

Authors:  Salah Mahmoudi; Sofia Henriksson; Irene Weibrecht; Stephen Smith; Ola Söderberg; Staffan Strömblad; Klas G Wiman; Marianne Farnebo
Journal:  PLoS Biol       Date:  2010-11-02       Impact factor: 8.029

7.  Neuron-specific expression of mutant superoxide dismutase is sufficient to induce amyotrophic lateral sclerosis in transgenic mice.

Authors:  Dick Jaarsma; Eva Teuling; Elize D Haasdijk; Chris I De Zeeuw; Casper C Hoogenraad
Journal:  J Neurosci       Date:  2008-02-27       Impact factor: 6.167

8.  Astrocytes as determinants of disease progression in inherited amyotrophic lateral sclerosis.

Authors:  Koji Yamanaka; Seung Joo Chun; Severine Boillee; Noriko Fujimori-Tonou; Hirofumi Yamashita; David H Gutmann; Ryosuke Takahashi; Hidemi Misawa; Don W Cleveland
Journal:  Nat Neurosci       Date:  2008-02-03       Impact factor: 24.884

9.  Survival motor neuron deficiency enhances progression in an amyotrophic lateral sclerosis mouse model.

Authors:  Bradley J Turner; Nicholas J Parkinson; Kay E Davies; Kevin Talbot
Journal:  Neurobiol Dis       Date:  2009-03-28       Impact factor: 5.996

10.  The threat of instability: neurodegeneration predicted by protein destabilization and aggregation propensity.

Authors:  Elizabeth M Meiering
Journal:  PLoS Biol       Date:  2008-07-29       Impact factor: 8.029

View more
  28 in total

1.  Genetic Modifiers for Neuromuscular Diseases.

Authors:  Kay-Marie Lamar; Elizabeth M McNally
Journal:  J Neuromuscul Dis       Date:  2014

2.  Single-Cell Analysis of SMN Reveals Its Broader Role in Neuromuscular Disease.

Authors:  Natalia Rodriguez-Muela; Nadia K Litterman; Erika M Norabuena; Jesse L Mull; Maria José Galazo; Chicheng Sun; Shi-Yan Ng; Nina R Makhortova; Andrew White; Maureen M Lynes; Wendy K Chung; Lance S Davidow; Jeffrey D Macklis; Lee L Rubin
Journal:  Cell Rep       Date:  2017-02-07       Impact factor: 9.423

Review 3.  Cajal bodies in neurons.

Authors:  Miguel Lafarga; Olga Tapia; Ana M Romero; Maria T Berciano
Journal:  RNA Biol       Date:  2016-09-14       Impact factor: 4.652

4.  CBP-mediated SMN acetylation modulates Cajal body biogenesis and the cytoplasmic targeting of SMN.

Authors:  Vanesa Lafarga; Olga Tapia; Sahil Sharma; Rocio Bengoechea; Georg Stoecklin; Miguel Lafarga; Maria T Berciano
Journal:  Cell Mol Life Sci       Date:  2017-09-06       Impact factor: 9.261

Review 5.  Disruption of RNA Metabolism in Neurological Diseases and Emerging Therapeutic Interventions.

Authors:  Julia K Nussbacher; Ricardos Tabet; Gene W Yeo; Clotilde Lagier-Tourenne
Journal:  Neuron       Date:  2019-04-17       Impact factor: 17.173

6.  Nuclear localization of SMN and FUS is not altered in fibroblasts from patients with sporadic ALS.

Authors:  Shingo Kariya; Jacinda B Sampson; Lesley E Northrop; Christopher M Luccarelli; Ali B Naini; Diane B Re; Michio Hirano; Hiroshi Mitsumoto
Journal:  Amyotroph Lateral Scler Frontotemporal Degener       Date:  2014-05-09       Impact factor: 4.092

Review 7.  Spinal muscular atrophy: journeying from bench to bedside.

Authors:  Tomoyuki Awano; Jeong-Ki Kim; Umrao R Monani
Journal:  Neurotherapeutics       Date:  2014-10       Impact factor: 7.620

8.  Genetic circuitry of Survival motor neuron, the gene underlying spinal muscular atrophy.

Authors:  Anindya Sen; Douglas N Dimlich; K G Guruharsha; Mark W Kankel; Kazuya Hori; Takakazu Yokokura; Sophie Brachat; Delwood Richardson; Joseph Loureiro; Rajeev Sivasankaran; Daniel Curtis; Lance S Davidow; Lee L Rubin; Anne C Hart; David Van Vactor; Spyros Artavanis-Tsakonas
Journal:  Proc Natl Acad Sci U S A       Date:  2013-06-11       Impact factor: 11.205

9.  Neurodegeneration in spinal muscular atrophy: from disease phenotype and animal models to therapeutic strategies and beyond.

Authors:  Umrao R Monani; Darryl C De Vivo
Journal:  Future Neurol       Date:  2014-01-01

10.  FUS-SMN protein interactions link the motor neuron diseases ALS and SMA.

Authors:  Tomohiro Yamazaki; Shi Chen; Yong Yu; Biao Yan; Tyler C Haertlein; Monica A Carrasco; Juan C Tapia; Bo Zhai; Rita Das; Melanie Lalancette-Hebert; Aarti Sharma; Siddharthan Chandran; Gareth Sullivan; Agnes Lumi Nishimura; Christopher E Shaw; Steve P Gygi; Neil A Shneider; Tom Maniatis; Robin Reed
Journal:  Cell Rep       Date:  2012-09-27       Impact factor: 9.423

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.